Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G for APOGEE THERAPEUTICS INC COMMON STOCK (APGE).
- Disclosed ownership: 11%.
- Date of event: 28 Feb 2026.
T. Rowe Price Investment Management, Inc. - 28 Feb 2026 SCHEDULE 13G Report for APOGEE THERAPEUTICS INC COMMON STOCK (APGE)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Security
- APOGEE THERAPEUTICS INC COMMON STOCK
- Symbol
- APGE
- Shares outstanding
- 54,989,619 shares
- Disclosed Ownership
- 6,213,827 shares
- Ownership
- 11%
- Form type
- SCHEDULE 13G
- Filing time
- 06 Mar 2026, 12:57:46 UTC
- Date of event
- 28 Feb 2026
- Next filing
- 08 Apr 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 11% ownership in APOGEE THERAPEUTICS INC COMMON STOCK (APGE) on 28 Feb 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 06 Mar 2026, 12:57.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11% | 6,213,827 | 5,879,389 | 0 | Ellen York | Vice President |